Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Winter;5(3):1-4.
doi: 10.14338/IJPT-18-00040.1. Epub 2019 Mar 21.

Pulmonary Function after Proton Therapy for Hodgkin Lymphoma

Lillie O'steen  1 , Jason Bellardini  2 , James Cury  2 , Lisa Jones  2 , Vandana K Seeram  2 , Nancy P Mendenhall  1 , Bradford S Hoppe  1
Affiliations

Pulmonary Function after Proton Therapy for Hodgkin Lymphoma

Lillie O'steen et al. Int J Part Ther. 2019 Winter.

Abstract

Purpose: Acute and late toxicity from chemotherapy, targeted therapy, and radiation therapy can cause significant morbidity among survivors of Hodgkin lymphoma (HL), including pulmonary dysfunction. Improved dosimetry may influence pulmonary function tests (PFTs), an objective and clinically significant measure of pulmonary toxicity. The present study investigates the impact of proton therapy on PFTs among HL survivors.

Patients and methods: We monitored 15 patients with mediastinal HL who were enrolled in an institutional HL trial. All patients were treated with combination chemotherapy plus involved-node proton therapy. All patients were to undergo PFTs before starting treatment and at approximately 6 and 12 months after completing proton therapy.

Results: Twelve patients were included in the analysis and 3 excluded. The mean forced vital capacity (FVC) was 96.2% ± 16.5% (mean ± SD) predicted at baseline and 98.2% ± 19.4% predicted at 12 months. The mean forced expiratory volume in 1 second (FEV1) was 96.7% ± 17.2% predicted at baseline and 97% ± 15.1% predicted at 12 months. The mean FEV1/FVC ratio was 99.5 ± 8.29 at baseline and 97.8 ± 8.02 at 12 months. The mean diffusing capacity of the lung for carbon monoxide was 81.4% ± 18.4% predicted at baseline and 95.7% ± 23.5% predicted at 12 months.

Conclusion: No unexpected changes were observed to the lungs as illustrated through follow-up PFTs. Long-term follow-up and validation in a larger cohort are needed.

Keywords: Hodgkin lymphoma; chemotherapy; proton therapy; pulmonary function tests; radiation therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Bradford S. Hoppe, MD, MPH, is an Associate Editor of The International Journal of Particle Therapy. The authors have no other conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Mean forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, and diffusing lung capacity for carbon monoxide (DLCO) predicted percentages at baseline and 6 and 12 months after proton therapy.
See this image and copyright information in PMC

References

    1. Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience. J Clin Oncol. 1994;12:2160–6. - PubMed
    1. Bossi G, Cerveri I, Volpini E, Corsico A, Baio A, Corbella F, Klersy C, Arico M. Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease. Ann Oncol. 1997;8(suppl 1):19–24. - PubMed
    1. Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14:1348–56. - PubMed
    1. Luna MA, Bedrossian CW, Lichtiger B, Salem PA. Interstitial pneumonitis associated with bleomycin therapy. Am J Clin Pathol. 1972;58:501–10. - PubMed
    1. Schunemann HJ, Dorn J, Grant BJ, Winkelstein W, Jr, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118:656–64. - PubMed

LinkOut - more resources